Skip to main content
MTRI logo

Mentari Therapeutics, Inc. (MTRI)

MTRINASDAQHealthcareBiotechnology

-Today:- (-)

Loading latest quote…

Market cap
-
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
-
Volume (live)
-
Avg. volume (3M)
-

Mentari Therapeutics (MTRI) Cash Flow Statement

In Q1 fiscal 2026 (quarter ended Mar 31, 2026), Mentari Therapeutics used $12.33M of cash in operating activities. Free cash flow was −$12.33M.

Mentari Therapeutics Cash Flow Statement Analysis

Values in dollars

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Mentari Therapeutics, Inc. (MTRI) - Annual data in dollars
Breakdown
Period ending
Operating Activities
Net Cash from Operating Activities
Investing Activities
Net Cash from Investing Activities
Financing Activities
Net Cash from Financing Activities
Summary
Net Change in Cash
Cash at Beginning of Period
Cash at End of Period
Free Cash Flow

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Mentari Therapeutics Cash Flow

What is Mentari Therapeutics' free cash flow?

Mentari Therapeutics had negative free cash flow of $12.33M in Q1 fiscal 2026 (quarter ended Mar 31, 2026).

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition